

## **PUBLICATIONS**

### **1) SCIENTIFIC PRESENTATIONS**

Gomes M, Olliaro P, Folb PI. What role can public health institutions play in drug development for the poor? Published in the proceedings of the international conference on The Rational Use of Qinghaosu and its Derivatives, Annecy, France. 1998.

Gomes M, Olliaro P, Folb PI. Developing Drugs for the Poor. Published in the Proceedings of the 2<sup>nd</sup> European Congress on Tropical Medicine and 4<sup>th</sup> Residential Meeting of the Royal Society of Tropical Medicine and Hygiene. Liverpool, England. September, 1998.

Folb PI and Olliaro P (1999) Ethics of new drug trials conducted in developing countries. MIM African Malaria Conference in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa, March 1999.

Wilkins J, Barnes K, Folb PI (1999) A cost analysis of first-line mild uncomplicated malaria treatment in the Tonga District of Mpumalanga. MIM African Malaria Conference in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa, March 1999.

Clarkson C, Matsabisa MG, Mpamhanga CP, Smith PJ, Folb PI, Campbell WE (1999) In vitro antiplasmodial activity of compounds MGCC/UCT-29/3/1 and MGCM/UCT-38/4/1 from plants 29 and 38, respectively. MIM African Malaria Conference in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa, March 1999.

Fivelman QL, Walden JC, Smith PJ, Folb PI, Barnes KI (1999) The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of *Plasmodium falciparum* in vitro. MIM African Malaria Conference in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa, March 1999.

Chlorproguanil/Dapsone: A rising dose-tolerance study in healthy human volunteers. Blockman, M. Smith, P., Evans, A., Gabriels, G., Folb, P., and Winstanley, P. (1998) 2<sup>nd</sup> European Congress on Tropical Medicine, Liverpool.

Ethics of new drug trials conducted in developing countries. Folb PI and Olliaro P. MIM African Malaria Conference, in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa. 14-19 March, 1999.

A cost analysis of first-line mild uncomplicated malaria treatment in the Tonga district of Mpumalanga. Wilkins J, Barnes K, Folb PI. MIM African Malaria Conference, in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa. 14-19 March, 1999.

In vitro antiplasmodial activity of compounds MGCC/UCT-29/3/1 and MGCM/UCT-38/4/1

from plants 29 and 38 respectively. Clarkson C, Matsabisa MG, Mpamhanga CP, Smith PJ, Folb PI and Campbell WE. MIM African Malaria Conference, in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa. 14-19 March, 1999.

The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of *Plasmodium falciparum* in vitro. Fivelman QL, Walden JC, Smith PJ, Folb PI and Barnes K. MIM African Malaria Conference, in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa. 14-19 March, 1999.

Expression of the p-glycoprotein-homologue 1 on *P. falciparum* food vacuoles. Lindt M, Elandalousin L, Folb PI and Smith PJ. MIM African Malaria Conference, in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa. 14-19 March, 1999.

In vitro resistance modifying effects of aqueous extracts of plant 3. Matsabisa M, Smith PJ, Folb PI and Campbell WE. MIM African Malaria Conference, in conjunction with the Southern African Malaria Project and the Roll Back Malaria Project of the World Health Organization. Durban, South Africa. 14-19 March, 1999.

The establishment of new research conducts for the integration of indigenous theory and practice with scientific systems of knowledge in the study of ethnopharmacology. SC Pefile, G Todd, PI Folb. The 6<sup>th</sup> International Congress of Ethnobiology. 23-28 November, 1998. Whakatane, Aotearoa, New Zealand.

New Drug Development: A World Health Organization Perspective. Public lecture. PI Folb. Annual General Meeting, Royal Society of Chemistry. Cape Town. March 1999.

International Organisation for Chemical Sciences in Development. 25 - 28 February 1996, Victoria Falls, Zimbabwe. MG Matsabisa, P Smith, P I Folb and WM Campbell  
The Antimalarial Plants from South Africa.

World Health Organisation, Double Tree Maryland USA 1997. Researching South African Traditional Medicines: Obstacles and Opportunities. MG Matsabisa, PI Folb

Multilateral Initiative on Malaria. International Convention Centre Durban, South Africa, March 14 - 19<sup>th</sup> 1999. In vitro Resistance Modifying Effects of Aqueous Extracts of Plant 3. MG Matsabisa PJ Smith PI Folb and WE Campbell

Multilateral Initiative on Malaria. International Convention Centre, Durban, South Africa, March 14 - 19<sup>th</sup> 1999. MG Matsabisa C Clarkson CP Mpamhanga PJ Smith WE Campbell and PI Folb. In vitro antiplasmodial activity of compounds MGCC/UCT-29/3/1 and MGCM/UCT-38/4/1 from plants 29 and 38 respectively.

UNESCO: The South African chemical and biological warfare programme in the apartheid era: revelations of the National Truth and Reconciliation Commission, with special reference to the general implications for the conduct of science. Chandré Gould and Peter I Folb . The

Millennium Symposium of Science, Society and Human Rights: Implementation of the Unesco Declaration on Science and the Use of Scientific Knowledge for the 21<sup>st</sup> Century. Regina, Canada. August, 2000. Plenary presentation and publication in symposium proceedings.

11<sup>th</sup> International Conference on Pharmaceutical Medicine Berlin/Germany, June 4 - 7, 2000. Clinical trials in countries where certain drugs are not available. Peter Folb, WHO collaborating centre for drug policy, University of Cape Town, South Africa and Melba Gomes, manager: Artesunate Task Force, WHO/TDR, World Health Organization (presentation and published abstract in conference proceedings).

Report to the World Health Organization on causality assessment of adverse events following immunisation: based on the discussion held at the World Health Organization by the World Health Organization global vaccine safety advisory committee. World Epidemiological Reports (1999). PI Folb.

Public lecture: 26. Royal Society of South Africa, Cape Town. Public lecture "Malaria – Is There A Way Forward?" Cape Town, South Africa.

Linking pharmacovigilance with rational drug use. How to bring experience from drug safety monitoring into drug information services, therapeutic guidelines, teaching and ADR prevention. Presentation at WHO meeting of national pharmacovigilance centres, Tunis, Tunisia. November, 2000. PI Folb.

Perverted Science and Twisted Loyalty. Chandré Gould and Peter Folb. Published on the leader page of the Sunday Independent on October 8, 2000. Report on a workshop held by Chandre Gould and Peter Folb with special invitees at the American Association for the Advancement of Science, Washington, DC, United States of America, on Monday 28th August 2000 on ethical repercussions of the South African apartheid-era chemical and biological warfare programme.

The role of pharmacovigilance centres. Harmonising drug safety monitoring: draft report of the World Health Organization. Ushma Mehta and Peter Folb. Report to the task force of the World Health Organization at WHO headquarters, Geneva. October, 2000. (For publication as a WHO report.)

Council for International Organizations of Medical Sciences (CIOMS): Current challenges in pharmacovigilance. Co-author of the monograph. PI Folb: 2001. World Health Organization.

B. Gumede and PI Folb. Role of the pro-inflammatory cytokines in the pathogenesis of murine cerebral malaria. Poster presented at the FAIS conference in Yaounde, Cameroon, February 2000.

D. Taylor. The Role of the neurotransmitter reuptake-blocking activity of antidepressants in reversing Chloroquine resistance *in vitro* in *Plasmodium falciparum*. (Presented at MIM African Malaria Conference, Durban, March 1999)

Donnelly A. van Schalkwyk, Jason Walden, Kurt Sales, Peter J. Smith *The Reversal Of Chloroquine Resistance in Plasmodium falciparum Using Combinations of Chemosensitisers* : Presented at the MIM African Malaria Conference, Durban, 1999.

MG Matsabisa, P Smith, P I Folb and WM Campbell. International Organisation for Chemical Sciences in Development. 25 - 28 February 1996, Victoria Falls, Zimbabwe  
The Antimalarial Plants from South Africa.

JL Kgekong, JC Brytenbach, JM Wachira, EM Tyobeka and MG Matsabisa.  
International Conference of Pharmaceutical and Pharmacological Societies of South Africa.  
Synthesis and evaluation of the biological activity of 2 and 8-trifluoromethyl and 2,8 bis (trifluoromethyl)-quinoline-4-carboxylic acid derivatives with heterocyclic moieties at position 4. 22-25<sup>th</sup> September 1996 Midrand South Africa

JP Dheyongera, CJ Van Der Schyff, TG Dekker, JM Wachira and MG Matsabisa.  
7<sup>th</sup> International Chemistry Conference in Africa and 34<sup>th</sup> Convention of the South African Chemical Institute 6 - 10<sup>th</sup> July 1998 University of Natal, Durban , South Africa. Synthesis and Antimalarial Evaluation of some Thiocridone Derivatives

JL Kgekong and MG Matsabisa. 7<sup>th</sup> International Chemistry Conference in Africa and 34<sup>th</sup> Convention of the South African Chemical Institute 6 - 10<sup>th</sup> July 1998 University of Natal, Durban , South Africa. Synthesis and Antimalarial Activity of Novel trifluoromethylquinoline Derivatives

MG Matsabisa and PI Folb. World Health Organisation, Double Tree Maryland USA 1997.  
Researching South African Traditional Medicines: Obstacles and Opportunities

MG Matsabisa PJ Smith PI Folb and WE Campbell. Multilateral Initiative on Malaria.  
International Convention Centre Durban, South Africa, March 14 - 19<sup>th</sup> 1999. *In vitro Resistance Modifying Effects of Aqueous Extracts of Plant 3*

MG Matsabisa C Clarkson CP Mpamhanga PJ Smith WE Campbell and PI Folb. Multilateral Initiative on Malaria. International Convention Centre, Durban, South Africa, March 14 - 19<sup>th</sup> 1999. *In vitro antiplasmodial activity of compounds MGCC/UCT-29/3/1 and MGCM/UCT-38/4/1 from plants 29 and 38 respectively*

MG Matsabisa . WHO GLP- workshop , Pharmacology, University of the Free State. June 26 – 29, 2000

MG Matsabisa. Round Table Discussion on Intellectual Property Issues at World Intellectual Property Organisation , Geneva, Switzerland, November 1999. Invited and presented a talk at a round table discussion on intellectual property rights on indigenous technology and knowledge by the World Intellectual Property Organisation (WIPO). This was held in Geneva, Switzerland on the 1<sup>st</sup> - 3<sup>rd</sup> November 1999. Travel and accommodation was at the expense of WIPO.

MG Matsabisa. Researching South African Traditional Medicines: Opportunities and Obstacles. Biotech SA '97. Biotechnology and Development in Southern Africa 2<sup>nd</sup> Grahamstown Conference. February 1997. Rhodes University, Grahamstown

MG Matsabisa. Researching South African Traditional Medicines, The experience of the National Research Centre for Traditional Medicines at UCT / UWC & MRC Unit

MG Matsabisa. 18<sup>th</sup> African Health Sciences Congress in collaboration with the 15<sup>th</sup> Epidemiological Society of Southern Africa Conference and the 6<sup>th</sup> African Regional Conference of the International Epidemiology Association Health Research in Africa, Meeting the Challenge Bellville Inn Cape Town April 14 – 19, 1997

MG Matsabisa. Natural Product Drug development: Can Universities alone deliver Marketable Drug? WHO Drug Metabolism Workshop for Africa, Pharmacology, University of the Free State. June 4 – 8, February 2001

MG Matsabisa. Researching South African Medicinal Plants. Antimalarial action of selected traditional malaria treatments. Medicines from Plants London United Kingdom June 25 – 27 1999

J. Walden, Q. Fivelman, P. Smith. In vitro Investigation of Pyronaridine Combination Therapy and Cross-resistance with Chloroquine.

Q. Fivelman, J. Walden, P. Smith, P. Folb, K. Barnes. The effect of Artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of *Plasmodium falciparum* in vitro. MIM Conference, Durban, 1999.

D. Taylor, J. Walden, A. Robbins, P. Smith. The role of neurotransmitter reuptake blocking activity of antidepressants in the reversal of chloroquine resistance in *Plasmodium falciparum* in vitro.

D. Van Schalkwyk, J. Walden, K. Sales, P. Smith. Reversal of chloroquine resistance in *Plasmodium falciparum* using combinations of chemosensitisers

Wilkins J, Barnes KI & Folb PI. A cost analysis of first-line mild uncomplicated malaria treatment in the Tonga district of Mpumalanga. Proceedings of the MIM African Malaria Conference, 14-19 March 1999, Durban, South Africa. Wellcome Trust, 1999: B-108.

N. Brine, W. Campbell, J. Bastida, C. Codina, F. Viladomat, A. Machocho and P. Smith; Natural Products Research in the New Millennium: 48th Annual Meeting of the Society for Medicinal Plant Research (GA), Zürich, 3-7 September, 2000: An acetylcholinesterase inhibiting alkaloid from the South African *Cyrtanthus sanguineus*.

J. Bastida, C. Codina, F. Viladomat, W. Campbell, J. Nair and N. Brine; VIIIth International Symposium on Flowerbulbs, Cape Town, 28-31 August 2000: Alkaloids from South African Amaryllidaceae species.

K. Saliba, P.J. B. Adams, Smith PJ. P-type and V-type ATPase components and chloroquine uptake of digestive vacuoles isolated from *Plasmodium falciparum*. 9th International Congress of Parasitology, Tokyo, 1998.

Smith, P.J., van Dyk, J. and Fredericks, A. An HPLC method for the simultaneous determination of Rifampicin, Isoniazid and Pyrazinamide in serum.. 29th World Congress of the International Union

Against Tuberculosis and Lung Disease Bangkok, Thailand 1998

McIlleron, H., Gabriels, G. Smith, P., Fourie, B., and Ellard, G. A standardized screening protocol for the in vivo assessment of rifampicin bioavailability. 29th World Congress of the International Union Against Tuberculosis and Lung Disease Bangkok, Thailand 1998.

Walden, J.C. , Fivelman, Q.L., Pietersen, R. and Smith P.J. (1999) In vitro investigation of pyronaradine combination therapy and cross-resistance with chloroquine. Multilateral Initiative on Malaria, African Malaria Conference, Durban, South Africa, 14 - 19 March 1999.

Lindt, M., Elandalloussi, L., Folb, P.I. and Smith, P.J. (1999) Expression of the P-glycoprotein homologue1 on P.falciparum food vacuoles. Multilateral Initiative on Malaria, African Malaria Conference, Durban, South Africa, 14 - 19 March 1999.

Elandalloussi, L.M. and Smith, P.J. (1999) Preparation of plasma membrane vesicles from Plasmodium falciparum. Multilateral Initiative on Malaria, African Malaria Conference, Durban, South Africa, 14-19 March 1999.

Clarkson, C., Matsabisa, M.G., Mpamhanga, C.P., Smith P.J., Folb, P.I. and Campbell, W.E. (1999). In vitro antiplasmodial activity of compounds MGCC/UCT-29/3/1 and MGCM/UCT-38/4/1 from plants 29 and 38 respectively. Multilateral Initiative on Malaria. African Malaria Conference, Durban South Africa, 14 - 19 March 1999

Matsabisa, M.G., Smith, P.J., Folb, P.I. and Campbell, W.E. In vitro resistance modifying effects of aqueous extracts of plant 3. Multilateral Initiative on Malaria. African Malaria Conference, Durban South Africa, 14 - 19 March 1999

van Schalkwyk, D.A., Walden, J., Sales, K. and Smith, P.J. (1999) The reversal of chloroquine resistance in Plasmodium falciparum using combinations of chemosensitisers. Multilateral Initiative on Malaria, African Malaria Conference, Durban, South Africa, 14-19 March 1999

Taylor, D. , Robins, A.H., Walden, J.C. and Smith, P.J. (1999) The role of the neurotransmitter reuptake-blocking activity of antidepressants in the reversal of chloroquine resistance in Plasmodium falciparum in vitro. Multilateral Initiative on Malaria, African Malaria Conference, Durban, South Africa, 14-19 March 1999

Manfredi, K and Smith P.J., (1999) Isolation and identification of a new anti-malarial naphthyl dihydroisoquinoline alkaloid from Ancistrocladus Tectorius International Natural Products Conference, Amsterdam, Netherlands, July 26 – 30 1999.

Fourie, P.B., van Niekerk C.H., Smith, P.J., McIlleron, H., Brooks, K., Fourie, T.G. and Gabriels, G. (1999) Bioavailability study comparing a three drug fixed dose combination paediatric powder formulation, rifampicin, isoniazid and pyrazinamide to equivalent doses of reference drugs as single doses. 30th IUATLD World Conference on Lung Health. Madrid, Spain September 1999 .

Fourie, P.B., Smith, P.J., McIlleron, H., van Niekerk C.H., Brooks, K., Fourie, T.G. and Gabriels, G. (1999) Bioavailability study comparing a four drug fixed dose combination tablet ( rifampicin, isoniazid, pyrazinamide and ethambutol) RIFAFOUR e200 to equivalent doses

of reference drugs as single doses. 30th IUATLD World Conference on Lung Health. Madrid, Spain September 1999 .

Fourie, P.B., Smith, P.J., McIlleron, H., van Niekerk C.H., Brooks, K., Fourie, T.G. and Gabriels, G. (1999) Bioavailability study comparing a two drug fixed dose combination tablet ( rifampicin and isoniazid) RIFINAH 150/150 to equivalent doses of reference drugs as single doses. 30th IUATLD World Conference on Lung Health. Madrid, Spain September 1999.

Fourie, P.B., Smith, P.J., McIlleron, H., van Niekerk C.H., Brooks, K., Fourie, T.G. and Gabriels, G. (1999) Bioavailability study comparing a four drug fixed dose combination tablet ( rifampicin, isoniazid, pyrazinamide and ethambutol) RIFAFOUR e275 to equivalent doses of reference drugs as single doses. 30th IUATLD World Conference on Lung Health. Madrid, Spain, September 1999.

Elandalloussi, L and Smith, P.J. Purification of Plasmodium facliparum plasma Membranes and charactrisation of the parasite plasma membrane ATPase activity. Molecular Approaches to Malaria 2 – 5 February 2000, Lorne, Victoria, Australia

McIlleron, H., Wash, P., Cockcroft, J., Wilkins, J., Fredericks, A., van Dyk, J., Burger, A., and Smith, P.J. Low and variable rifampicin levels in tuberculosis patients. TB into the new millenium. 14 – 18 July 2000, Palm Cove, Queensland, Australia

Cridland JS. “Fitting Survival Data to the Classical Probability Curve.”; “Towards a Classification of the Indications for the Use of Traditional Medicines.”; “Rapid Entry of Data into Databases.” At 2<sup>nd</sup> International Conference on Pharmaceutical & Pharmacological Sciences, Cape Town 3-6 Oct. 1999

Pefile S. Sixth International Congress of Ethnobiology (New Zealand, November 1998): The Establishment Of New Research Conducts For The Integration Of Indigenous Theory And Practice With Scientific Systems Of Knowledge In The Study Of Ethnopharmacology.

Pefile S. Symposium On African Medicinal And Indigenous Food Plants And The Role Of Traditional Medicine In Health Care (Swaziland, October 1999): A Multidisciplinary Approach to Medicinal Plant Research.

Pefile S. Predictions for Percutaneous Penetration Conference (France, April 1997): The Diffusion Properties of Rooperol Tetra-acetate from Different Topical Vehicles

Pefile S. Gordon Research Conference (USA, August 1997): The Application of Supersaturation Techniques to Overcome the Barrier Properties of Skin.

Ntutela SC. The *in vitro* efficacy tests against *Mycobacterium tuberculosis* of plants used to treat tuberculosis in South Africa. Presented at the “Joint Meeting for 2000 Years of Natural Products Research” held in Amsterdam, Holland 25 – 30 June 1999

## 2) PUBLICATIONS

Folb PI. Cytostatics and immunosuppressive drugs. In: Meyler’s Side Effects of Drugs, 14<sup>th</sup>

edition. Editors: MNG Dukes, PI Folb and others. Elsevier Science Publishers. Pages 1538-1595. 2000.

Folb PI. Intravenous infusions – solutions and emulsions. In: Meyler's Side Effects of Drugs, 14<sup>th</sup> edition. Editors: MNG Dukes, PI Folb and others. Elsevier Science Publishers. Pages 1140-1170. 2000.

Saliba KJ, Folb PI, Smith PJ. Role for the Plasmodium falciparum digestive vacuole in chloroquine resistance. *Biochemical Pharmacology*, 56, 313-320, 1998.

Walubo A, Smith P and Folb PI (1998) The role of oxygen free radicals in isoniazid-induced hepatotoxicity. *Meth Find Exp Clin Pharmacol*, 20(8), 649-655.

Valodia P, Folb PI, Seymour MA, Kies BM. Benefits of a clinical pharmacokinetic service in optimising phenytoin use in the Western Cape. *South African Medical Journal*, 88, 873-875, 1998.

Chapter in *The International Textbook of Clinical Pharmacology*; editors C van Boxtel and R Edwards. Publishers – Wiley. Title of chapter: Drug Policy. In conjunction with Marc Blockman, co-authors. Publication in early 2001.

Developing A National System For Dealing With Adverse Events Following Immunization. U Mehta, JB Milstien, P Duclos, PI Folb. *Bulletin Of The World Health Organization*, 2000, 78 (2), 170-177.

Disabling Chemicals In Project Coast And Associated Activities; Chandré Gould and Peter Folb. Chapter for inclusion in the book "Disabling Chemicals" - a review of Harvard Sussex program. Publication – early 2001.

The role of professionals in the South African Chemical and Biological Warfare Program. Chandré Gould and Peter Folb. Prepared for publication in the Australian journal, *Minerva*. For publication early 2001.

The South African Chemical and Biological Warfare Program: An Overview; Chandré Gould and Peter Folb. Prepared for *Non-Proliferation Review*, the journal of the Monterey Institute. For publication in early 2001.

Gould C and Folb PI (2000) The South African Chemical and Biological Warfare Program: An Overview. *The Nonproliferation Review of the Monterey Institute of International Studies*. Fall-Winter 2000, volume 7, no. 2, 10-23.

Pefile S. *South African Journal of Science* (Vol 93, April, 1997, 147-150): Transdermal Drug Delivery Systems: Vehicle Design and Formulation Considerations.

Pefile S. Journal of Liquid Chromatography and Related Techniques (Vol 20, No 18, 1997, 3061-3072): The Validation of a New Stability- Indicating HPLC Technique Developed for the Quantitative Analysis of Rooperol Tetra-acetate.

Pefile S. International Journal of Pharmaceutics (Vol 161, 1998, 237-243): Rooperol Tetra-acetate Release from Topical Bases: In Vitro Studies Using Silicone Membrane.

Cridland, JS & Koonin, S. Use of Traditional Medicines - Towards a Classification. S Afr Med J 2001; 91: 489-491.

Dale Taylor, Jason C. Walden, Ashley H. Robins, Peter J. Smith. Role of the neurotransmitter reuptake-blocking activity of antidepressants in reversing Chloroquine resistance *in vitro* in *Plasmodium falciparum*. Antimicrobial Agents and Chemotherapy 44:10 pp 2689-2693. 2000

Kelly Chibale, John R. Moss, Margaret Blackie, Donnelly van Schalkwyk and Peter J. Smith: *New Amine and Urea Analogs of Ferrochloroquine: Synthesis, Antimalarial Activity In Vitro and Electrochemical Studies*: Tetrahedron Letters 2000, volume 41 (issue 32), pages 6231-6235.

Coetzee, G.A., A.F. Strachan, D.R. van der Westhuyzen, H.C. Hoppe, M.S. Jeenah & F.C. de Beer. 1986. Serum amyloid A-containing human high density lipoprotein 3. *Journal of Biological Chemistry* 21 : 9644-9651.

Strachan, A.F., F.C. de Beer, G.A. Coetzee, H.C. Hoppe, M.S. Jeenah & D.R. van der Westhuyzen. 1986. Characteristics of apo-SAA-containing HDL<sub>3</sub> in humans. *Protides of the Biological Fluids* 34 : 359-362.

Dormehl, I.C., A. van Wyk, W. Pilloy, O. Knoesen, R. de Winter, L. Jacobs & H.C. Hoppe. 1989. Using the "integral spleen" method of radiorenogram analysis and the baboon model to compare the diagnostic usefulness of Tc-99m diethyleneaminepenta-acetic acid to that of various Tc-99m mercaptoacetyltriglycine formulations and I-123 hippuran. *American Journal of Physiologic Imaging*. 4 : 23-27.

Hoppe, H.C., J.A. Verschoor & A.I. Louw. 1991. *Plasmodium falciparum* : a comparison of synchronisation methods for *in vitro* cultures. *Experimental Parasitology* 72 : 464-467.

Hoppe, H.C., J. Coetzee & A.I. Louw. 1992. *Plasmodium falciparum* : isolation of intact and erythrocyte-free trophozoites from sorbitol lysates. *Parasitology* 104 : 379-385.

Crause, J.C., J.A. Verschoor, J. Coetzee, H.C. Hoppe, J.N. Taljaard, R. Gothe & A.W.H. Neitz. 1993. The localization of a paralysis toxin in granules and nuclei of prefed female *Rhipicephalus evertsi evertsi* tick salivary glands. *Experimental and Applied Acarology* 17 : 357-363.

Cywes, C., N.L. Godenir, H.C. Hoppe, R.R. Scholle, L.M. Steyn, R.E. Kirsch & M.R.W. Ehlers. 1996. Nonopsonic binding of *Mycobacterium tuberculosis* to human complement receptor type 3 (CR3; Mac-1; CD11b/CD18) expressed in Chinese Hamster Ovary Cells. *Infection and Immunity* 64 : 5373-5383.

Hoppe, H.C., B.J.M. de Wet, C. Cywes, M. Daffé & M.R.W. Ehlers. 1997. Identification of phosphatidylinositol mannoside as a mycobacterial adhesin mediating both direct and opsonic binding to nonphagocytic mammalian cells. *Infection and Immunity* 65 : 3896-3905.

Cywes, C., H.C. Hoppe, M. Daffé & M.R.W. Ehlers. 1997. Nonopsonic binding of *Mycobacterium tuberculosis* to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent. *Infection and Immunity* 65 : 4258-4266.

Ngô, H.M., H.C. Hoppe & K.A. Joiner. 2000. Differential sorting and post-secretory targeting of proteins in parasitic invasion. *Trends in Cell Biology* 10 : 67-72.

\*Hoppe, H.C., M. Yang, H. M. Ngô & K.A. Joiner. 2000. Targeting to the rhoptry organelles of *Toxoplasma gondii* involves evolutionarily conserved protein sorting mechanisms. *Nature Cell Biology* 2 : 449-456

Hoppe, H.C. and K.A. Joiner. 2000. Cytoplasmic tail motifs mediate endoplasmic reticulum localization and export of transmembrane reporters in the protozoan parasite *Toxoplasma gondii*. *Cellular Microbiology* 2 : 569-578.

Liendo, A., T.T Stedman, H.M. Ngo, S. Chaturvedi, H.C. Hoppe & K.A. Joiner. 2001. *Toxoplasma gondii* ADP-ribosylation factor 1 mediates enhanced release of constitutively secreted dense granule proteins. *Journal of Biological Chemistry* 276 : 18272-18281.

B Fourie, G Pillai, H McIlleron, P Smith, R Panchagnula, G Ellard. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to the single drug reference preparations administered in loose combination. Model protocol. World Health Organization, Communicable Diseases Cluster 1999. WHO/CDS/99.274.

H McIlleron, G Gabriels, P Smith, B Fourie, G A Ellard. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability. *Int J Lung Tuberc Dis* 1999, 3(11): S329-S335.

G Pillai, N Padayatchi, PC Onyebujoh, H McIlleron, PJ Smith, G Gabriels, PB Fourie. Recent Bioequivalence Studies on Fixed Dose Combination (FDC) anti-tuberculosis drug formulations available on the global market. *Int J Lung Tuberc Dis* 1999, 3(11): S309-S316.

Q. Fivelman, J. Walden, P. Smith, P. Folb, K. Barnes (1999)  
The effect of Artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of *Plasmodium falciparum* in vitro.  
*Transactions of the Royal Society of Tropical Medicine and Hygiene Jul, 93:4, 429-32*

Timothy J. Egan, Roger Hunter, Catherine H. Kaschula, Helder M Marques and Jason C. Walden (1999) Structure-function Relationships in Aminoquinolines: The Effect of Amino and Chloro Groups on the Quinoline-haematin Complex Formation, Inhibition of B-haematin formation and Antimalarial Activity. *Journal of Medicinal Chemistry* 43: 283-291

D. Taylor, J. Walden, A. Robins, P. Smith

The role of neurotransmitter reuptake blocking activity of antidepressants in the reversal of chloroquine resistance in *in vitro Plasmodium falciparum*. (2000)  
Antimicrobial Agents and Chemotherapy 44:10, 2689-2692

Wilder-Smith CH, Hill L, Wilkins J & Denny L. Effects of morphine and tramadol on somatic and visceral sensory function and gastrointestinal motility after abdominal surgery. *Anesthesiology* 1999; 91(3): 639-647.

Baker L, Barnes K. New antimalarial treatment for KwaZulu Natal. *South Afr Med J* 2001; 91 (5): 358-9.

Kachur SP, Abdulla S, Barnes K, Mshinda H, Durrheim DN, Kitua A, Bloland P. Mothers, malaria and resistance. *Trop Med Int Health* 2001; 6: 324-325.

Fivelman Q, Walden JC, Smith PJ, Folb PI, 1999 The effect of artesunate combined with standard anti-malarials against Chloroquine sensitive and chloroquine resistant strains of *P. falciparum in vitro* *Trans Roy Soc Trop Med* 93, 429-432

Blumberg L, Barnes KI 1999 What is the future of malaria treatment in Africa? (Editorial) *Southern African Journal of Epidemiology and Infection* 14 (3): 63  
Assistant editor of the *South African Medicines Formulary* 4<sup>th</sup> Edition 1998

KI Barnes, Durrheim D, Blumberg L 1998 Quinine as unofficial contraceptive – concerns about safety and efficacy (letter) *SAMJ* 88 (10): 1280-1282

Anokbonggo W, Ogwal Okeng J, Waako P; 1997. Antimalarial prescription patterns in Mulago Hospital. *East African Medical Journal*

Taylor, B and Smith P.J. Does AIDS impair the absorption of antituberculous drugs. (1998) *International Journal of Tuberculosis and Lung Disease* 2 (8) 670 - 675

Saliba, K.J., Folb, P.I. and Smith, P.J. A role for the *Plasmodium Falciparum* digestive vacuole in chloroquine resistance. (1998) *Biochemical Pharmacology* 56, 313 - 320.

Walubo, A., Smith, P., and Folb, P.I. The role of oxygen free radicals in isoniazid-induced hepatotoxicity. (1998) *Meth Find Exp Clin Pharmacol* 20(8): 649-655

Smith, P.J., van Dyk, J. and Fredericks, A. Determination of Rifampicin, Isoniazid and Pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma (1999) *International Journal of Tuberculosis and Lung Disease* 3 (11) 325 - 328

McIlleron, H., Gabriels, G. Smith, P., Fourie, B., and Ellard, G. The development of a standardized screening protocol for the *in vivo* assessment of rifampicin bioavailability (1999) *International Journal of Tuberculosis and Lung Disease* 3 (11) S329 – S335

Pillai, G., Padayatchi, N., Onyebujoh, P.C., McIlleron, H., Smith, P.J., Gabriels, G., and Fourie, P.B. Recent bioequivalence studies on fixed dose combination antituberculosis Drug formulations on the global market. (1999) *International Journal of Tuberculosis and Lung Disease* 3 (11) S309 – S316.

Fivelman, Q.L., Walden, J.C., Smith, P.J., Folb, P.I. and Barnes, K.I. The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of *Plasmodium falciparum*. (1999) Transactions of the Royal Society of Tropical Medicine and Hygiene 93, 429 – 432 .

Peden, M., van der Spuy, J., Smith, P. and Bautz., P. Substance Abuse and Trauma in Cape Town (2000) South African Medical Journal 90 (3), 251-255

Campbell, W.E., Nair, J.J., Gammon, D.W., Codina, C., Bastida, J., Viladomat, F., Smith, P.J. and Albrecht, C.F. (2000) Bioactive alkaloids from *Brunsvigia radulosa*. Phytochemistry 53, 587 - 591

Taylor, D.E., Robins, A.H., Walden, J. and Smith P.J. The role of neurotransmitter reuptake-blocking activity of antidepressants in reversing chloroquine resistance in vitro in *Plasmodium falciparum*. (2000) Antimicrobial agents and chemotherapy. 44, 2689 - 2692

Chibale, K., Moss, J.R., Blackie, M., van Schalkwyk, D., and Smith, P.J. New amine and urea analogs of ferrochloroquine: synthesis, antimalarial activity in vitro and electrochemical studies, (2000) Tetrahedron Letts 41 6231 – 6235

Pillai, G., Ellard, G.A., Smith, P.J. and Fourie, P.B. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-Tuberculosis formulations. (2001) International Journal of Tuberculosis and Lung Disease (accepted for publication)

### **3) SPECIAL REPORTS**

Bioavailability study comparing Rifafour combination tablets as a single dose to equivalent doses of Noristan-isoniazid, Rimactane, Rozide and Mycrol as a single dose, in healthy volunteers. McIlleron, H., Smith, P.J., Gabriels, G., Viljoen, E. and Fourie, P.B. (1998).

Bioavailability study comparing a fixed dose combination tablet formulation (120mg Rifampicin, 50mg Isoniazid and 300mg Pyrazinamide) with equivalent doses of single drug reference products. Dr.H.McIlleron, Dr.P.Smith, Mr.G.Gabriels, Dr.B.Fourie.

Bioavailability study comparing Rifinah Combination Paediatric Powder (Rifampicin 60mg and Isoniazid 30mg) as a single dose to equivalent doses of NORISTAN-ISONIAZID®, and RIFADIN® as a single dose, in healthy volunteers. (1998) Dr.H.McIlleron, Dr.S. Lawrenson, Dr.P.Smith, Mr.G.Gabriels, Dr.B.Fourie, Mrs.E Viljoen.

Bioavailability study comparing Rifater Combination Paediatric Powder (Rifampicin 60mg, Isoniazid 30mg and Pyrazinamide 150mg) as a single dose to equivalent doses of NORISTAN-ISONIAZID®, ROZIDE® and RIFADIN® as a single dose, in healthy volunteers. (1998) Dr.H.McIlleron, Dr.S. Lawrenson, Dr.P.Smith, Mr.G.Gabriels, Dr.B.Fourie, Mrs.E Viljoen.

Bioavailability study comparing Rifinah Combination Tablets (Rifampicin 150mg and

Isoniazid 75mg) as a single dose to equivalent doses of NORISTAN-ISONIAZID®, and RIFADIN® as a single dose, in healthy volunteers. (1998) Dr.H.McIlleron, Dr.S. Lawrenson, Dr.P.Smith, Mr.G.Gabriels, Dr.B.Fourie, Mrs.E Viljoen.

Bioavailability study comparing Rifinah Combination Tablets (Rifampicin 150mg and Isoniazid 150mg) as a single dose to equivalent doses of NORISTAN-ISONIAZID®, and RIFADIN® as a single dose, in healthy volunteers. (1998) Dr.H.McIlleron, Dr.S. Lawrenson, Dr.P.Smith, Mr.G.Gabriels, Dr.B.Fourie, Mrs.E Viljoen.

Bioavailability study comparing Rifafour E275 combination tablets (Rifampicin 150mg, Isoniazid 75mg, Pyrazinamide 400mg and Ethambutol 275mg) as a single dose to equivalent doses of NORISTAN-ISONIAZID®, RIFADIN®, PYRAZINAMIDE® and ROLAB ETHAMBUTOL®, as a single dose, in healthy volunteers. (1999) Dr.H.McIlleron, Dr.S. Lawrenson, Dr.P.Smith, Mr.G.Gabriels, Dr.B.Fourie, Mrs.E Viljoen.

Effect of bulk and fat content in four different types of meals on the bioavailability of a single 900 mg dose of rifapentine in healthy male volunteers (1999) Dr.H.McIlleron, Dr.S. Lawrenson, Dr.P.Smith, Mr.G.Gabriels, Dr.B.Fourie

The bioavailability and bioequivalence of rifampicin, ethambutol, isoniazid and pyrazinamide as a single dose in a fixed dose combination formulation, Rimstar 4-FDC, compared to equivalent doses of single drug reference standards of the four drugs. (1999) Dr.H.McIlleron, Dr.P.Smith, Dr. D Harwarden, Mr.G.Gabriels, Dr.B.Fourie,

The bioavailability and bioequivalence of rifampicin, isoniazid and pyrazinamide as a single dose in a fixed dose combination formulation, Rimcure 3-FDC, compared to equivalent doses of single drug reference preparations of the three drugs. (1999) Dr.H.McIlleron, Dr.P.Smith, Dr. D Harwarden, Mr.G.Gabriels, Dr.B.Fourie.

The bioavailability and bioequivalence of rifampicin, isoniazid and pyrazinamide as a single dose in a fixed dose combination formulation, Rimcure 3-FDC Intermittent compared to equivalent doses of single drug reference preparations of the three drugs. (1999) Dr.H.McIlleron, Dr.P.Smith, Dr. D Harwarden, Mr.G.Gabriels, Dr.B.Fourie.

The bioavailability and bioequivalence of rifampicin and isoniazid in a single dose in a fixed dose combination formulation, Rimaactazid 150/75, compared to equivalent doses of single drug reference preparations of the two drugs. (1999) Dr.H.McIlleron, Dr.P.Smith, Dr. D Harwarden, Mr.G.Gabriels, Dr.B.Fourie.

The bioavailability and bioequivalence of rifampicin and isoniazid in a single dose in a fixed dose combination formulation, Rimaactazid 150/150, compared to equivalent doses of single drug reference preparations of the two drugs. (1999) Dr.H.McIlleron, Dr.P.Smith, Dr. D Harwarden, Mr.G.Gabriels, Dr.B.Fourie.

Bioavailability study comparing Rifater Combination Dispersable Tablets (Rifampicin 60mg, Isoniazid 30 mg and Pyrazinamide 150mg) as a single dose to equivalent doses of NORISTAN-ISONIAZID®, ROZIDE and RIFADIN® as a single dose, in healthy volunteers. (2000) Dr.H.McIlleron, Dr.P.Smith, Dr. D. Harwarden, Mr.G.Gabriels, Dr.B.Fourie.

Bioavailability study comparing Rifinah Combination Tablets (Rifampicin 60mg and Isoniazid 30mg) as a single dose to equivalent doses of NORISTAN-ISONIAZID®, and RIFADIN® as a single dose, in healthy volunteers. (2000) Dr.H.McIlleron, Dr.P.Smith, Dr. D. Harwarden, Mr.G.Gabriels, Dr.B.Fourie.

The bioavailability and bioequivalence of four drugs in a single dose of a fixed dose combination formulation, Myrin P, compared to an equivalent dose of single drug reference preparations of rifampicin, isoniazid, pyrazinamide and ethambutol (2001). Dr. H. McIlleron, Dr. P.J. Smith, Dr B. Fourie, and Mr. G. Gabriels.

The South African chemical and biological warfare programme in the apartheid era: revelations of the national Truth and Reconciliation Commission, with special reference to the general implications for the conduct of science. Chandré Gould and Peter I Folb . The millennium symposium of science, society and human rights: implementation of the Unesco declaration on science and the use of scientific knowledge for the 21<sup>st</sup> century. Regina, Canada. August, 2000.

Report to the who meeting of the task force on severe malaria regarding the scientific content of the artesunate rectal development programme, the gaps in the science which may be filled when the drug is in use, and the manner in which we should take rectal artesunate forward for control of malaria. M Gomes and PI Folb. Oxford, United Kingdom. 16<sup>th</sup> September 2000.

PI Folb: Report to the World Health Organization on causality assessment of adverse vents following immunisation: based on the discussion held at the world health organization by the world health organization vaccine safety advisory committee, 5-6<sup>th</sup> june 2000.

PI Folb: Linking pharmacovigilance with rational drug use. : how to bring experience from drug safety monitoring into drug information services, therapeutic guidelines, teaching and adr prevention. Presentation at who meeting of national pharmacovigilance centres, tunis, tunisia. November, 2000. PI Folb.

Report on a workshop held by Chandre Gould and Peter Folb with special invitees at the American Association for the Advancement of Science, Washington, DC, United States of America, 28th august 2000, on ethical repercussions of the South African apartheid-era chemical and biological warfare programme. (Reported in the Sunday Independent, 08.10.2000)

#### 4) ARTICLES IN PRINT

Kgokong J.L., Smith P.P., Matsabisa M.G and Jali V.L.M.  
1,2,4-Tiazino-[5,6b] indole Derivatives: Effects of the Trifluoromethyl Group and its *in vitro* Antimalarial Activity.  
Submitted to: Journal of Bioorganic and Medicinal Chemistry

Kgokong J.L and Matsabisa M.G. Assessment of *in vitro* Antimalarial Potential of some N,N-bis(trifluoromethylquinoline) alkane diamine Derivatives.  
Submitted to: Journal of Pharmaceutical Sciences

Matsabisa M.G. Smith P.J , Folb P.I and Campbell W.E  
The in vitro Chloroquine Resistance reversal by the Aqueous Extracts of *Sclerocarya birrea*  
In Preparation for submission to an Planta Medica

Kgokong J.L, Matsabisa M.G, Breytenbach J.C. The *In vitro* Antimalarial Activity of Novel Trifluoromethyl- and Bis (trifluoromethyl) quinoline Derivatives  
Submitted to: Arznei-Forsch/Drug Research

Robibaro, B., H.C. Hoppe, M. Yang, I. Coppens, H.M. Ngô, T.T. Stedman, K. Paprotka & K.A. Joiner. 2001. Endocytosis in different lifestyles of protozoan parasitism: role in nutrient uptake with special reference to *Toxoplasma gondii*. *International Journal of Parasitology* (in press)

Wilkins J, Barnes KI, Valentine N & Folb PI (2001). An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: Development of a model for estimating recurrent direct costs. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. In press.

Durrheim DN, Sharp BL, Barnes KI, 2001 Sentinel malaria surveillance – merely research or indispensable public health tool? Editorial . South African Medical Journal (in press)

Mabuza A, Govere J, Durrheim D, Mngomezulu N, Bredenkamp B, Barnes K, Sharp B 2001 Therapeutic efficacy of sulfadoxine – pyrimethamine for uncomplicated plasmodium falciparum malaria three years after introduction in Mpumalanga Province, South Africa. South African Medical Journal (in press)

Bredenkamp BLF, Sharp BL, Durrheim DN, Barnes KI 2001 Failure of Sulfadoxine – pyrimethamine in treating Plasmodium falciparum malaria in KwaZulu Natal province. South Afr Med J (in press)

Wilkins JJ, Folb PI, Valentine N and Barnes KI, 2001 An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: Development of a model for estimating direct costs Trans R Soc Trop Med (in press)

Barnes KI, Gunston G, Edwards R, Mehta U Drug Safety: a shared responsibility. 2001 Drug Information Journal (in press)